Blockade of endothelin receptors attenuates end-organ damage in homozygous hypertensive Ren-2 transgenic rats

Kidney and Blood Pressure Research

Volumn 27, Issue 4, 2004, Pages 248-258

  Dvorak P ^a,c   Kramer, Herbert J ^b   Bäcker, Angela ^b   Malý, Jan ^a   Kopkan, Libor ^a   Vaněčková, Ivana ^a   Vernerová, Zdena ^a,c   Opočenský, Martin ^a   Tesař, Vladimír ^c   Bader, Michael ^d   Ganten, Detlev ^d   Janda, Jan ^c   Červenka, Luděk ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b UNIVERSITY OF BONN   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Bosentan; End organ damage; Endothelin; Hypertension; Renin angiotensin system

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE REGIMEN; HYPERTENSION; KIDNEY INJURY; MALE; MORPHOLOGY; NONHUMAN; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TAIL ARTERY; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CREATININE; ELECTROLYTES; ENDOTHELIN-1; HOMOZYGOTE; HYPERTENSION, RENAL; KIDNEY; MALE; ORGAN SIZE; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; RENIN; SODIUM, DIETARY; SULFONAMIDES;

EID: 4644320772     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080052     Document Type: Article

References (48)

1. Hall JE, Brands MW: The renin-angiotensinaldosterone system: Renal mechanisms and circulatory homeostasis; in Seldin DW, Giebisch G (eds): The Kidney: Physiology and Pathophysiology. Philadelphia, Lippincott/ Williams & Wilkins, 2000, pp 1009-1046.
2. Moreau P, Schiffrin EL: Role of endothelins in animal models of hypertension: Focus on cardiovascular protection. Can J Physiol Pharmacol 2003;81:511-521.
3. Bader M, Peters J, Baltatu O, Muller DM, Luft FC, Ganten D: Tissue renin-angiotensin systems: New insight from experimental animal models in hypertension research. J Mol Med 2001;79:76-102.
4. Roux S, Breu V, Ertel SI, Clozel M: Endothelin antagonism with bosentan: A review of potential applications. J Mol Med 1999;77:364-376.
5. Emori T, Hirata Y, Ohta K, Kanno K, Schichiri M, Maumo F: Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells. Biochem Biophys Res Commun 1989;160:93-100.
6. Sung CP, Arleth AJ, Storer BL, Ohlstein EH: Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J Pharmacol Exp Ther 1994;271:429-437.
7. Kohno M, Takeshi H, Ikeda M, Yokokawa K, Fukui T, Yasunari K, Kurihra N, Takeda T: Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int 1992;42:860-866.
8. Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, Granger JP: Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol 2001;280:R1388-R1392.
9. Sasser JM, Pollock JS, Pollock DM: Renal endothelin in chronic angiotensin II hypertension. Am J Physiol 2002;283:R243-R248.
10. Ficai S, Herizi A, Mimran A, Jover B: Endothelin blockade in angiotensin II hypertension: Prevention and treatment studies in the rat. Clin Exp Pharmacol Physiol 2001;28:1100-1103.
11. d'Uscio LV, Moreau P, Shaw S, Takase H, Barton M, Luscher TF: Effects of chronic ETAreceptor blockade in angiotensin II-induced hypertension. Hypertension 1997;29:435-441.
12. Muller DN, Mervaala EMA, Schmidt F, Park JK, Dechend R, Generesch E, Breu V, Löffler BM, Ganten D, Schneider W, Haller H, Luft FC: Effect of Bosentan on NF-κB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 2000;36:282-290.
13. A receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension 1999;33:954-960.
14. Saam T, Ehmke H, Haas C, Ritz E, Amann K: Effect of endothelin blockade on early cardiovascular remodeling in the one-clip, two-kidney hypertension of the rat. Kidney Blood Press Res 2003;26:325-332.
15. Mullins J, Peters J, Ganten D: Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990;344:541-544.
16. Langheinrich M, Lee MA, Bohm M, Pinto YM, Ganten D, Paul M: The hypertensive Ren-2 transgenic rat TGR(mRen2)27 in hypertension research. Characteristics and functional aspects. Am J Hypertens 1996;9:506-512.
17. Blezer ELA, Nicolay K, Goldschmeding R, Jansen GH, Koomans HA, Rabelink TJ, Joles JA: Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in strokeprone hypertensive rats. Hypertension 1999;33:137-144.
18. Touyz RM, Turgeon A, Schiffrin EL: Endothelin-A-receptor blockade improves renal function and doubles the life-span of stroke-prone hypertensive rats. J Cardiovasc Pharmacol 2000;36:S300-S304.
19. Callahan MF, Li P, Ferrario CM, Ganten D. Morris M: Salt-sensitive hypertension in (mREN-2)27 transgenic rats. Hypertension 1996;27:573-577.
20. Heller J, Hellerova S: Long-term effect on blood pressure of early brief treatment by different antihypertensive agents: A study in the Prague hypertensive rat. Kidney Blood Press Res 1998;21:445-451.
21. Yagil C, Sapojnikov M, Katni G, Ilan Z, Zangen SW, Rosenmann E, Yagil Y: Proteinuria and glomerulosclerosis in the Sabra genetic model of salt susceptibility. Physiol Genomics 2002;9:167-178.
22. Bäcker A, Bokemeyer D, Kramer HJ: Endothelin synthesis and receptors in porcine kidney. Acta Physiol Scand 2001;171:105-112.
23. Bohlender J, Gerbaulet S, Krämer J, Gross M, Kirchengast M, Dietz R: Synergistic effects of AT1 and ETA receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension 2000;35:992-997.
24. Muller DN, Mullally A, Dechend R, Park JK, Fiebeler A, Pilz B, Loffler BM, Blum-Kaelin D, Masur S, Dehmlow H, Johannes D, Haller H, Luft FC: Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension 2002;40:840-846.
25. Rossi GP, Sacchetto A, Rizzoni D, Bova S, Porteri E, Mazzocchi G, Belloni AS, Bahcelioglu M, Nussdorfer GG, Pessina AC: Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms. Arterioscler Thromb Vas Biol 2000;20:949-956.
26. Seccia TM, Belloni AS, Kreutz R, Paul M, Nussdorfer GG, Pessina AC, Rossi GP: Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol 2003;41:666-673.
27. Whitworth CE, Veniant MM, Firth JD, Cumming AD, Mullins JJ: Endothelin in the kidney in malignant phase hypertension. Hypertension 1995;26:925-931.
28. Whitworth CE, Fleming S, Cumming AD, Morton JJ, Burns NJT, Williams BC, Mullins JJ: The spontaneous development of malignant phase hypertension in transgenic Ren-2 rats. Kidney Int 1994;46:1528-1532.
29. Kantachuvesiri S, Haley CS, Fleming S, Kurian K, Whitworth CE, Wenham P, Kotelevtsev Y, Mullins JJ: Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats. Kidney Int 1999;56:414-420.
30. B receptor imbalance differentiates salt-sensitive from salt-resistant spontaneous hypertension. Hypertension 2001;37:275-280.
31. B receptors in the renal medulla. Hypertension 2003;41:1359-1363.
32. De Nucci G, Gryglewski RJ, Warner TD, Vane JR: Receptor-mediated release of endotheliumderived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 1998;85:2334-2338.
33. B activation in vivo and modulation by receptor antagonism. Am J Physiol 1998;274:R131-R138.
34. A receptors. Am J Physiol 2004;286:F660-F668.
35. Nussdorfer GG, Rossi GP, Malendowicz LK, Mazocchi G: Autocrine-paracrine endothelin system in the physiology and pathology of steroid-secreting tissues. Pharmacol Rev 1999;51:403-438.
36. Park JB, Schiffrin EL: Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: Role of endothelin-1. Am J Hypertens 2002;15:164-169.
37. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL: Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003;42:49-55.
38. Mervaala E, Muller D, Schmidt F, Park JK, Gross V, Bader M, Breu V, Ganten D, Haller H, Luft F: Blood pressure-independent organ damage in rats with human renin and angiotensinogen. Hypertension 2000;35:587-594.
39. Shindo T, Kurihara H, Maemura K, Kurihara Y, Ueda O, Suzuki H, Kuwaki T, Ju K, Wang Y, Ebihara A, Nishimatsu H, Moriyama N, Fukuda M, Akimoto Y, Hirano H, Moriat H, Kumada M, Yazaki Y. Nagai R, Kimura K: Renal damage and salt dependent hypertension in aged transgenic mice overexpressing endothelin-1. J Mol Med 2002;80:105-116.
40. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, Sleuning WD, Theuring F: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99:1380-1389.
41. Guijarro C, Egido J: Transcription factor-κB (NF-κB) and renal disease. Kidney Int 2001;59:415-424.
42. Luft FC: Endothelin, nephropathy, and blood pressure. J Mol Med 2002;80:69-70.
43. Pinto YM, Buikema H, van Gilst WH, Scholtens E, van Geel PP, de Graeff PA, Wagner J, Paul M: Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. J Mol Med 1997;75:371-377.
44. Teisman AC, Pinto YM, Buikema H, Flesch M, Böhm M, Paul M, van Gilst WH: Dissociation of blood pressure reduction from endorgan damage in TGR(mREN2)27 transgenic hypertensive rats. J Hypertens 1998;16:1759-1765.
45. Montgomery HE, Kiernan LA, Whitworth CE, Fleming S, Unger T, Gohlke P, Mullins JJ, McEwan JR: Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. J Hypertens 1998;16:635-643.
46. Kang N, Walther T, Tian XL, Bohlender J, Fukamizu A, Ganten D, Bader M: Reduced hypertension-induced end-organ damage in mice lacking cardiac and renal angiotensinogen synthesis. J Mol Med 2002;80:359-366.
47. Alexander RW: Theodor Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: A new perspective. Hypertension 1995;25:495-500.
48. Reckelhoff JF, Romero CJ: Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol 2003;284:R893-R912.